Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSIFebruary 25, 2013
Durata announced preliminary, top-line results that dalbavancin met its primary endpoints in the DISCOVER 2 Phase 3 study. DISCOVER 2 results follow the recent release of data from DISCOVER 1, which also met its primary and secondary endpoints.
Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical PainFebruary 25, 2013
Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, initiated a Phase 2 study of AYX1, its lead drug candidate for the prevention of post-surgical pain.
Cubist has the exclusive right to acquire Adynxx following the data readout of Adynxx’s Phase 2 trial for its lead candidate, AYX1, a potential treatment for the reduction of acute pain and prevention of persistent and chronic pain following surgery.